Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a fast-growing type of lung cancer that typically starts in the bronchi and is often associated with smoking. It can spread quickly to other parts of the body.
Durvalumab for Limited Stage Small Cell Lung Cancer
We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you weigh more than 30 kg?
- Do you have limited stage small cell lung cancer (SCLC) that can be treated with radiation?
- Are you pregnant or breastfeeding?
- Have you had any major surgery in the last 6 weeks?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Complexo Hospitalario Universitario A Coruna
Medical Oncology
A Coruña, Spain
Hospital Universitario De Badajoz
Medical Oncology
Badajoz, Spain
Hospital Universitario De Cruces
Medical Oncology
Barakaldo, Spain
Sponsor: Astrazeneca Farmaceutica Spain S.A.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.